Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06549465 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)
A Phase 2 study of PSMA PET-Positive Castration-Resistant Prostate Cancer, sponsored by Convergent Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 9
- Study locations
NCT06549465: Recruiting Phase 2 study of PSMA PET-Positive Castration-Resistant Prostate Cancer, sponsored by Convergent Therapeutics.
NCT06549465 is a Phase 2 study of PSMA PET-Positive Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Convergent Therapeutics. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06549465, a Phase 2 study of PSMA PET-Positive Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Convergent Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a three-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225). Part 1 will consist of one administration of In-111-rosopatamab tetraxetan to characterize the biodistribution of the radioantibody to target organs and prostate cancer lesions. Participants then will be enrolled into either Part 2 (Dose Optimization) or Part 3 (Dose Escalation and Expansion) depending on their prior treatment history. Participants qualifying for Part 2 will be randomized to receive Ac-225 rosopatamab tetraxetan in a single fractionated cycle (dose administration on Day 1 and Day 15) at either 45 or 60 kBq/Kg. Participants qualifying for Part 3 must have received prior Lu-177-PSMA-radioligand therapy and will receive Ac-225 rosopatamab tetraxetan in a single fractionated cycle at 45, 55, or 60 kBq/Kg. Dose limiting toxicities (DLTs) will be monitored in Part 3 to determine the recommended phase 2 dose (RP2D), and the study may enroll additional participants to be treated with the RP2D dose level. Participants enrolled into any part will attend study visits which will include blood samples, electrocardiogram (ECG), radiographic imaging, and physical examinations along with other assessments.
Conditions Studied
Interventions
- BIOLOGICAL In-111 rosopatamab tetraxetan
- BIOLOGICAL 45 kBq/kg Ac-225 rosopatamab tetraxetan
- BIOLOGICAL 55 kBq/kg Ac-225 rosopatamab tetraxetan
- BIOLOGICAL 60 kBq/kg Ac-225 rosopatamab tetraxetan
Study Locations (9)
New York
- Laura & Isaac Perlmutter Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - New York
- New York Presbyterian/Weill Cornell Medical Center - New York
California
- University of California San Diego - San Diego
Massachusetts
- Dana-Farber Cancer Institute - Boston
Missouri
- Washington University in St. Louis - St Louis
Nebraska
- X Cancer Omaha / Urology Cancer Center - Omaha
North Carolina
- Duke University Medical Center - Durham
Ohio
- The Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-08-06 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
What NCT06549465 shows while recruiting
NCT06549465 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with PSMA PET-Positive Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which In-111 rosopatamab tetraxetan is the first listed.
NCT06549465 lists 9 locations in 7 states (New York, California, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06549465 about?
NCT06549465 is a clinical study titled "Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)". This is a three-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225). Part 1 will consist of one administration of In-111-rosopatamab tetraxetan to characterize the biodistribution of the radioantibody to targe...
What is the current status of trial NCT06549465?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-08-06. Estimated completion is 2027-04.
What conditions does trial NCT06549465 study?
This clinical trial studies the following conditions: PSMA PET-Positive Castration-Resistant Prostate Cancer.
What interventions are being tested in trial NCT06549465?
The interventions under investigation include: In-111 rosopatamab tetraxetan (BIOLOGICAL), 45 kBq/kg Ac-225 rosopatamab tetraxetan (BIOLOGICAL), 55 kBq/kg Ac-225 rosopatamab tetraxetan (BIOLOGICAL), 60 kBq/kg Ac-225 rosopatamab tetraxetan (BIOLOGICAL).
Who is sponsoring clinical trial NCT06549465?
This trial is sponsored by Convergent Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06549465 being conducted?
This trial has 9 study locations across California, Massachusetts, Missouri, Nebraska, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06549465's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI